By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Regen BioPharma  

4700 Spring Street
Suite 304
La Mesa  California  91942  U.S.A.
Phone: 619-702-1404 Fax: 619-330-2328


Company News
Regen BioPharma Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell For Solid Tumors 2/3/2016 6:51:20 AM
Regen BioPharma Submits Application To FDA For Orphan Drug Designation For Its HemaXellerate Product 1/26/2016 6:51:52 AM
Regen BioPharma And The NIH To Collaborate 1/20/2016 7:31:42 AM
Regen BioPharma President Harry Lander Provides Open Letter To Shareholders On Company's Progress And Developments 1/14/2016 8:00:26 AM
Regen BioPharma Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6 12/16/2015 9:35:44 AM
Regen BioPharma Receives FDA Clearance To Initiate Clinical Trial Of Hemaxellerate 12/15/2015 7:38:34 AM
Regen BioPharma Attracts Top Researchers To Scientific Advisory Board 12/1/2015 11:13:06 AM
Regen BioPharma Submits Response To FDA Questions On Hemaxellerate Investigational New Drug Application 11/17/2015 7:36:39 AM
Regen BioPharma Initiates NR2F6 T Cell Immunotherapy Preclinical Program With Dr. Santosh Kesari, Director Of Neuro-Oncology At John Wayne Cancer Institute 11/12/2015 8:43:08 AM
Regen BioPharma Files Patent Application On Personalized Checkpoint Inhibitor Cancer Immunotherapy 11/4/2015 10:34:26 AM